Literature DB >> 31009858

An AMH-based FSH dosing algorithm for OHSS risk reduction in first cycle antagonist protocol for IVF/ICSI.

Negjyp Sopa1, Elisabeth Clare Larsen2, Helene Westring Hvidman2, Anders Nyboe Andersen2.   

Abstract

The study assessed the impact of an AMH algorithm for FSH dosing in 589 patients to maintain pregnancy rates while minimizing OHSS rates in 1st antagonist cycles for IVF. Patients with low AMH < 12 pmol/L (n = 203) had maximal stimulation with corifollitropin, patients with AMH 12-32 pmol/L (n = 256) had standard stimulation with 150 IU/day of rFSH and patients with AMH > 32 pmol/L (n = 130) had minimal stimulation with 112 IU/day of HP-hMG. The proportion of patients with targeted (5-14) number of oocytes at retrieval was: Low AMH 42%, intermediate AMH 76% and high AMH 67% (p < 0.001). Low responses (≤ 4 oocytes) was found in 55%, 16% and 26% (p < 0.001) in the low, intermediate and high AMH group, respectively. Excessive responses (≥15 oocytes) was found in 2.5%, 6.2% and 6.1% in the low, intermediate and high AMH groups, respectively. Despite the high proportion of low responses, the ongoing pregnancy rates in the high AMH group was 41% per started cycle. A total of 14 patients had OHSS preventive actions like agonist triggering (n = 12) and/or cryopreservation of all embryos (n = 4) and all avoided OHSS. Three (0.5%) patients were admitted to hospital with severe OHSS, and all occurred after hCG triggering and all cases were late OHSS in relation to pregnancy. All were in the high AMH group after aspiration of 10-15 follicles. The conclusion is that among high AMH patients, low dose HP-hMG will limit the mean number of oocytes, without compromising pregnancy rates. The OHSS risk will be low, but as long as transfer after hCG triggering is used OHSS will occur unless a cut-off for OHSS preventive actions as low as 10-15 follicles is used.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Anti-Müllerian hormone (AMH); Antral follicle count (AFC); IVF/ICSI; OHSS

Year:  2019        PMID: 31009858     DOI: 10.1016/j.ejogrb.2019.02.001

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  4 in total

1.  Effect and Relationship of Seasons on the High Risk of Ovarian Hyperstimulation Syndrome After Oocyte Retrieval in Patients With Polycystic Ovary Syndrome.

Authors:  Yurong Cao; Hao Shi; Yue Ma; Linna Ma; Jun Zhai
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-26       Impact factor: 5.555

2.  The Essential Role of Body Weight in Adjusting Gn Dosage to Prevent High Ovarian Response for Women With PCOS During IVF: A Retrospective Study.

Authors:  Rujun Zeng; Hanxiao Chen; Xun Zeng; Lang Qin
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-01       Impact factor: 6.055

3.  Response to ovulation induction treatments in women with polycystic ovary syndrome as a function of serum anti-Müllerian hormone levels.

Authors:  Stylianos Vagios; Caitlin R Sacha; Karissa C Hammer; Irene Dimitriadis; Kaitlyn E James; Charles L Bormann; Irene Souter
Journal:  J Assist Reprod Genet       Date:  2021-05-01       Impact factor: 3.357

4.  Prediction of severe ovarian hyperstimulation syndrome in women undergoing in vitro fertilization using estradiol levels, collected ova, and number of follicles.

Authors:  Ivan Madrazo; Monserrat Fabiola Vélez; Josue Jonathan Hidalgo; Ginna Ortiz; Juan José Suárez; Leonardo M Porchia; M Elba Gonzalez-Mejia; Esther López-Bayghen
Journal:  J Int Med Res       Date:  2020-08       Impact factor: 1.671

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.